Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare ultra-long-acting insulin degludec with glargine for efficacy and safety in insulin-naive patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs (OADs). RESEARCH DESIGN AND METHODS: In this 1-year, parallel-group, randomized, open-label, treat-to-target trial, adults with type 2 diabetes with A1C of 7−10% taking OADs were randomized 3:1 to receive once daily degludec or glargine, both with metformin. Insulin was titrated to achieve prebreakfast plasma glucose (PG) of 3.9−4.9 mmol/L. The primary end point was confirmation of noninferiority of degludec to glargine in A1C reduction after 52 weeks in an intent-to-treat analysis. RESULTS: In all, 1,030 participants (mean age 59 years; baseline A1C 8.2%) were randomized (degludec 773, glargine 257). Reduction in A1C with degludec was similar (noninferior) to that with glargine (1.06 vs. 1.19%), with an estimated treatment difference of degludec to glargine of 0.09% (95% CI −0.04 to 0.22). Overall rates of confirmed hypoglycemia (PG <3.1 mmol/L or severe episodes requiring assistance) were similar, with degludec and glargine at 1.52 versus 1.85 episodes/patient-year of exposure (PYE). There were few episodes of nocturnal confirmed hypoglycemia in the overall population, and these occurred at a lower rate with degludec versus glargine (0.25 vs. 0.39 episodes/PYE; P = 0.038). Similar percentages of patients in both groups achieved A1C levels <7% without hypoglycemia. End-of-trial mean daily insulin doses were 0.59 and 0.60 units/kg for degludec and glargine, respectively. Adverse event rates were similar. CONCLUSIONS: Insulins degludec and glargine administered once daily in combination with OADs provided similar long-term glycemic control in insulin-naive patients with type 2 diabetes, with lower rates of nocturnal hypoglycemia with degludec.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of the phase III trials with IDeg were designed as treat-to-target trials striving for an ambitious (fasting) blood glucose level target of 4–5 mmol/L (70–90 mg/dL).”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a result of the treat-to-target design, a comparison can be made in terms of differences in endpoints such as hypoglycaemia (but not, for example, HbA1c), as illustrated in Table 4 [48–54].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“the concentration of IDeg-specific antibodies and antibodies cross-reacting with IDeg and human insulin was found to be low in studies in patients with T1DM [48, 49] or T2DM [50, 53], indicating that the risk of immunogenicity with IDeg is minimal.”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Ethical principles for medical research involving human subjects
(2003) · Manual for Research Ethics Committees · doi:10.1017/cbo9780511550089.027 · Cited by 2,585
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
(2014) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/jwiet-2014-0117 · Cited by 2,473
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Self-citationHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794 · cited 1×
“Additionally, the risk, consequences, and fear of hypoglycemia remain a significant limiting factor in intensifying insulin therapy and optimizing glycemic control (9).”
Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects
(2009) · JIBL · doi:10.1515/jibl.2009.12 · Cited by 768
Research works printed but not linked: 2
- International Diabetes foundation. Diabetes atlas 5th edition [article online], 2011. Available from http://www.idf.org/diabetesatlas/5e/the-global-burden. Accessed 10 January 2012
- Heise, 2011, The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state (Abstract), Diabetes, 60, A263
Cited by
Items 101–200 of 342
Management of Type 2 Diabetes Mellitus in Older Patients: Current and Emerging Treatment Options
Moghissi, E. S. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0039-6 · Cited by 34
King, A. B., Philis‐Tsimikas, A., Kilpatrick, E. S., Langbakke, I. H., Begtrup, K., & Vilsbøll, T. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0405 · Cited by 28
Self-citationKusunoki, Y., Katsuno, T., Miyakoshi, K., Ikawa, T., Nakae, R., Ochi, F., Tokuda, M., Akagami, T., Murai, K., Miuchi, M., et al. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0048-5 · Cited by 28
Zhou, W., Tao, J., Zhou, X., & Chen, H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0624-4 · Cited by 31
Bode, B. W., CHAYKIN, L. B., Sussman, A., Warren, M., Niemeyer, M., Rabøl, R., & Rodbard, H. W. (2014) · Endocrine Practice · doi:10.4158/ep13411.or · Cited by 28
Self-citationEvans, M., McEwan, P. C., & FOOS, V. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.975234 · Cited by 30
Kapitza, C., Bode, B. W., Ingwersen, S. H., Jacobsen, L. V., & Poulsen, P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.549 · Cited by 28
Aso, Y., Suzuki, K., Chiba, Y., Sato, M., Fujita, N., Takada, Y., Murano, S., & Kuroda, H. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.06.007 · Cited by 29
Galindo, R. J., Pasquel, F. J., Vellanki, P., Alicic, R., Lam, D. W., Fayfman, M., Migdal, A. L., Davis, G. M., Cardona, S., Urrutia, M. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14544 · Cited by 26
“However, insulin degludec, in both randomized and observational studies, has been associated with significant lower rates of overall symptomatic and nocturnal hypoglycaemic events,(14,16,17) as well as less day-to-day and within-day glycaemic variability compared with other basal insulin analogues.(13,14,18) The safet…”
Cai, X., Gao, X., Yang, W., & Ji, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1400011 · Cited by 28
Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes
Berard, L., Antonishyn, N., Arcudi, K., Blunden, S., CHENG, A. Y. Y., Goldenberg, R., Harris, S. B., Jones, S., Mehan, U., Morrell, J., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0375-7 · Cited by 26
Mauricio, D., & HRAMIAK, I. M. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14supp1.2 · Cited by 25
Kerr, D. E., Edelman, S. V., Vespasiani, G., & Khunti, K. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.04.006 · Cited by 26
Morieri, M. L., Rigato, M., Frison, V., Simioni, N., D'Ambrosio, M., Tadiotto, F., Paccagnella, A., Lapolla, A., Avogaro, A., & Fadini, G. P. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13840 · Cited by 26
Model predictive control for dose guidance in long acting insulin treatment of type 2 diabetes
Aradóttir, T. B., Boiroux, D., Bengtsson, H. L., Kildegaard, J., Jensen, M. L., Jørgensen, J. B., & Poulsen, N. K. (2019) · IFAC Journal of Systems and Control · doi:10.1016/j.ifacsc.2019.100067 · Cited by 26
Thyde, D. N., Mohebbi, A., Bengtsson, H. L., Jensen, M. L., & Mørup, M. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820912411 · Cited by 26
Flexibly timed once‐daily dosing with degludec: a new ultra‐long‐acting basal insulin
Josse, R. G., & Woo, V. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12114 · Cited by 24
Woo, V. C. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.007 · Cited by 23
Holmes, R. S., Crabtree, E. A., & McDonagh, M. S. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13614 · Cited by 24
Patient safety and minimizing risk with insulin administration – role of insulin degludec
Atkin, S. L., & Aye, M. (2014) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s59566 · Cited by 31
György, J., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Winkler, G., & Wittmann, I. (2017) · Diabetologia Hungarica · doi:10.24121/dh.2017.1 · Cited by 39
Basal insulin analogs: From pathophysiology to therapy. What we see, know, and try to comprehend?
Monnier, L., Colette, C., & Owens, D. R. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.003 · Cited by 24
A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
Gurung, T., Waugh, N. R., O’Hare, J. P., & Shyangdan, D. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s34418 · Cited by 22
Clinical use of insulin degludec: Practical experience and pragmatic suggestions
Kalra, S., & Gupta, Y. (2015) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.153918 · Cited by 22
Maiorino, M. I., Petrizzo, M., Capuano, A., Giugliano, D., & Esposito, K. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.895812 · Cited by 22
Harris, S. B., Abrahamson, M. J., Ceriello, A., Charpentier, G., Evans, M., Lehmann, R., Liebl, A., Linjawi, S., Holt, R. I. G., Hosszúfalusi, N., et al. (2020) · Drugs · doi:10.1007/s40265-019-01245-3 · Cited by 22
Cheng, A. Y. Y., Wong, J., Freemantle, N., Acharya, S. H., & Ekinci, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00925-8 · Cited by 20
Lim, S. I., & Kwon, I. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1048504 · Cited by 21
Model for Simulating Fasting Glucose in Type 2 Diabetes and the Effect of Adherence to Treatment
Aradóttir, T. B., Boiroux, D., Bengtsson, H. L., Kildegaard, J., Orden, B. V., & Jørgensen, J. B. (2017) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2017.08.2527 · Cited by 21
Ahdab, M. A., Leth, J., Knudsen, T., Vestergaard, P., & Clausen, H. G. (2021) · Biochemical Engineering Journal · doi:10.1016/j.bej.2021.108170 · Cited by 20
Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
Miccoli, R., Dardano, A., Bianchi, C., & Prato, S. D. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s40097 · Cited by 19
Rossetti, P., Ampudia‐Blasco, F. J., & Ascaso, J. F. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12256 · Cited by 20
Warren, M., CHAYKIN, L. B., Jabbour, S. A., Sheikh‐Ali, M., Hansen, C. T., Nielsen, T. S. S., & Norwood, P. C. (2017) · Clinical Diabetes · doi:10.2337/cd15-0058 · Cited by 20
Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes
Henao, D. C., Múñoz, Ó., Gómez, A. M., Rondón, M., Colon, C. A., Chica, L. G., Rubio, C., Vargas, F. M. L., Calvachi, M. A., & Perea, A. M. (2018) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2018.03.003 · Cited by 21
Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience
Chan, W. B., Chen, J.-F., Goh, S., Vũ, T. T. H., Isip-Tan, I. T., Mudjanarko, S. W., Bajpai, S., Mabunay, M. A., & Bunnag, P. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s143046 · Cited by 19
Dong, Z.-Y., Feng, J., & Zhang, J. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.09.012 · Cited by 20
Bedros, J. R., Jermendy, G., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Lengyel, C., Várkonyi, T. T., Winkler, G., & Wittmann, I. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.20 · Cited by 21
IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes
Hughes, E. (2016) · Primary care diabetes · doi:10.1016/j.pcd.2015.12.005 · Cited by 18
Shimoda, S., Sato, M., Sekigami, T., Motoshima, H., Yoshimura, R., Fukuda, K., Matsuo, Y., Noda, H., Okubo, M., Ichimori, S., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12496 · Cited by 19
EINHORN, D. F., Handelsman, Y., Bode, B. W., Endahl, L. A., Mersebach, H., & King, A. B. (2015) · Endocrine Practice · doi:10.4158/ep14523.or · Cited by 18
Self-citationConcepts and clinical use of ultra-long basal insulin
Eliaschewitz, F. G., & Barreto, T. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0117-1 · Cited by 20
CHENG, A. Y. Y., Bailey, T. S., Mauricio, D., & Roussel, R. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3329 · Cited by 17
Drab, S. R., & Philis‐Tsimikas, A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1361 · Cited by 18
Self-citationSu, W., Li, C., Zhang, L., Lin, Z., Tan, J. H., & Xuan, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00683-2 · Cited by 19
the RESTORE-1 Study Group, Laviola, L., Porcellati, F., Bruttomesso, D., Larosa, M., Rossi, M. C., & Nicolucci, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00982-z · Cited by 16
Insulin Degludec: A Novel Basal Insulin Analogue
Goldman, J. D., Patel, D. K., & Schnee, D. M. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r351 · Cited by 17
Haldrup, S., Lapolla, A., Gundgaard, J., & Wolden, M. L. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1669613 · Cited by 16
White, J. R. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.86 · Cited by 16
Haluzík, M., Fulcher, G., Pieber, T. R., Bardtrum, L., Tutkunkardas, D., & Rodbard, H. W. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13261 · Cited by 17
Self-citationEfficacy and Safety of Ideglira in Older Patients with Type 2 Diabetes
Lingvay, I., Handelsman, Y., Linjawi, S., Vilsbøll, T., Halladin, N., Ranc, K., & Liebl, A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0284 · Cited by 18
Self-citationAppropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist
Patel, D. K., Triplitt, C. L., & Trujillo, J. M. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00907-8 · Cited by 17
Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
Kalra, S. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0047-6 · Cited by 18
Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes
Chatterjee, S., Khunti, K., & Davies, M. J. (2019) · Drugs · doi:10.1007/s40265-018-1048-6 · Cited by 15
Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy
Kumar, A. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.904851 · Cited by 17
Bohn, B., Zimmermann, A., Wagner, C., Merger, S. R., Dunstheimer, D., Kopp, F., Gollisch, K. S. C., Zindel, V., & Holl, R. W. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.031 · Cited by 15
Woo, V. C., Berard, L., & Roscoe, R. S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00915-w · Cited by 17
Kobuke, K., Yoneda, M., Nakanishi, S., Ohno, H., Maeda, S., & Egusa, G. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12373 · Cited by 16
Landstedt‐Hallin, L., Gundgaard, J., Ericsson, Å., & Ellfors-Zetterlund, S. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1277194 · Cited by 17
Frias, P. F., & Frías, J. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0926-8 · Cited by 15
Johnson, E. L., Frías, J. P., & Trujillo, J. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1452515 · Cited by 16
Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice
Davis, C. S., Fleming, J. W., Malinowski, S. S., Brown, M. A., & Fleming, L. W. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000076 · Cited by 17
Cardiovascular effects of basal insulins
Mannucci, E., Giannini, S., & Dicembrini, I. (2015) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s43300 · Cited by 15
Lajara, R., Cengiz, E., & Tanenberg, R. J. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1298522 · Cited by 15
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
Kerlan, V., Thuillier, P., & Alavi, Z. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s54953 · Cited by 15
The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin
Shaefer, C. F., & Anderson, J. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1103640 · Cited by 14
Modelling of fasting glucose-insulin dynamics from sparse data
Aradóttir, T. B., Boiroux, D., Bengtsson, H. L., & Poulsen, N. K. (2018) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2018.8512792 · Cited by 14
Sen, A., Mohanraj, P. S., Laxmi, V., Ashique, S., Vasudevan, R., Aldahish, A. A., Velu, A., Das, A., Ehsan, I., Islam, A., et al. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101305 · Cited by 17
Suzuki, J., Yamakawa, T., Oba, M. S., Nagakura, J., Shigematsu, E., Tamura, H., Takahashi, K., Okamoto, Y., Sakamoto, R., Shinoda, M., et al. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0309 · Cited by 13
Lega, I. C., Yale, J.-F., Chadha, A., Paty, B., Roscoe, R., Snider, M., Steier, J., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.08.003 · Cited by 12
Okada, M., Okada, M., Nishigami, J., Yamaaki, N., Furukawa, K., Ohyama, K., Shimada, T., & Sai, Y. (2015) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-015-0027-2 · Cited by 12
Vilsbøll, T., Vora, J. P., Jarlov, H., Kvist, K., & Blonde, L. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0376-0 · Cited by 12
Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus
Frier, B. M., Ratzki‐Leewing, A. A., & Harris, S. B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13732 · Cited by 12
Shimoda, S., Sakamoto, W., Hokamura, A., Matsuo, Y., Sekigami, T., Ichimori, S., Iwashita, S., Ishii, N., Otsu, K., Yoshimura, R., et al. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0179 · Cited by 12
Long-Acting Basal Insulins: A Review of the More Recently Approved Agents
Aragon, K. G., Elmaoued, A. A., Pham, N.-Y. T., Conklin, J. R., & Ray, G. M. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000266 · Cited by 12
Scheen, A. J., Schmitt, H., Jiang, H. H., & Iványi, T. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.10.005 · Cited by 11
Luo, J., Qu, Y., Zhang, Q., Chang, A. M., & Jacober, S. J. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817736315 · Cited by 11
Rosenstock, J., BAJAJ, H. S., Lingvay, I., & Heller, S. R. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003930 · Cited by 12
Glargine and degludec: Solution behaviour of higher dose synthetic insulins
Adams, G. G., Alzahrani, Q. E., Jiwani, S. I., Meal, A. G., Morgan, P. S., Coffey, F., Kök, S. M., Rowe, A. J., Harding, S. E., Chayen, N. E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06642-w · Cited by 11
Fulcher, G., Mehta, R., Fita, E. G., Ekelund, M., & Bain, S. C. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0531-0 · Cited by 12
Meneghini, L., Blonde, L., Gill, J., Dauchy, A., Bacevicius, A., Strong, J. L., & Bailey, T. S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14116 · Cited by 11
Sun, M.-F., Xu, Y.-F., Yuan, J., & Fang, W. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.06.011 · Cited by 11
Recent Advances in Insulin Therapy for Diabetes
Ahmad, A. (2014) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410006 · Cited by 11
Optimizing management of glycaemia
Chatterjee, S., Khunti, K., & Davies, M. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.002 · Cited by 15
Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety
Ponzani, P., Berra, C., Lelio, A. D., Sindaco, P., Loreto, C. D., Reggiani, F., Lucisano, G., & Rossi, M. C. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0511-4 · Cited by 12
The future of insulin therapy for patients with type 2 diabetes mellitus.
Tibaldi, J. M. (2013) · PubMed · Cited by 14
Switching basal insulins in type 2 diabetes: practical recommendations for health care providers
Anderson, S. L., Trujillo, J. M., Anderson, J. E., & Tanenberg, R. J. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1419048 · Cited by 11
Vargas‐Uricoechea, H., & Pablo, F. J. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.001 · Cited by 11
The current schemes of insulin therapy: Pro and contra
Riddle, M. C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108817 · Cited by 15
Takahashi, H., Nishimura, R., Onda, Y., Ando, K., Tsujino, D., & Utsunomiya, K. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1293652 · Cited by 9
Hompesch, M., Patel, D. K., LaSalle, J. R., & Bolli, G. B. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1568136 · Cited by 10
Wilding, J. P. H., & Bain, S. C. (2015) · Diabetic Medicine · doi:10.1111/dme.13021 · Cited by 8
Brunton, S., Kruger, D. F., & Funnell, M. M. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.1.34 · Cited by 8
Ilag, L. L., Costigan, T. M., Deeg, M. A., Pollom, R. K., Chang, C. L., Konrad, R. J., & PRINCE, M. J. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0253-8 · Cited by 8
Tailoring the Padova Type 2 Diabetes Simulator for Treatment Guidance in Target Populations
VISENTIN, R., Schiavon, M., Bonet, J., Riz, M., Wagenhuber, B., & Man, C. D. (2024) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2024.3352153 · Cited by 9
Insulin degludec is a new ultra-long-acting insulin analogue
Dedov, I. I., & Shestakova, M. V. (2014) · Diabetes Mellitus · doi:10.14341/dm2014291-104 · Cited by 8
Vora, J. P., Seufert, J., Solberg, H., Kinduryte, O., Johansen, T., & Hollander, P. A. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12621 · Cited by 8
Self-citationThewjitcharoen, Y., Yenseung, N., Malidaeng, A., Butadej, S., Chotwanvirat, P., Krittiyawong, S., Thammawiwat, C., & Himathongkam, T. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0899-5118 · Cited by 8
Concentrated Insulins: A Review and Recommendations.
Gonzalvo, J. D., Patel, D. K., & Olin, J. L. (2017) · Europe PMC (PubMed Central) · Cited by 8
Cummings, M. H., Cao, D., Hadjiyianni, I., Ilag, L. L., & Tan, M. H. (2018) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0059-2 · Cited by 8
Insulines lentes aujourd’hui et demain : pour quels besoins non ou mal couverts ?
Monnier, L., & Colette, C. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70725-4 · Cited by 7
Metadata
- Authors
- Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators
- Affiliations
- Mount Sinai Hospital (CA)
- Scripps Whittier Diabetes Institute, La Jolla, California
- Centre Hospitalier Universitaire de Nantes (FR)
- Metabolic Institute of America, Tarzana, California
- Endocrine and Metabolic Consultants, Rockville, Maryland
- Novo Nordisk (Denmark) (DK)
- Universitair Ziekenhuis Leuven (BE)
- Corresponding author
- Mathieu, Chantal
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-11-14
- Volume
- 35
- Issue
- 12
- Pages
- 2464-2471
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3507614
- OpenAlex
- W1965832529
- Semantic Scholar
- d71056ccc92e22c6deda4b52fb5b27aada6b0588
- Cited by
- 336
- References
- 34
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 12 · 2023: 15 · 2022: 16 · 2021: 13 · 2020: 17 · 2019: 29 · 2018: 32 · 2017: 38 · 2016: 30 · 2015: 41 · 2014: 42 · 2013: 35 · 2012: 4
- FWCI
- 31.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Amarin Corporation
- MannKind Corporation
- Halozyme
- Novo Nordisk
- Genentech
- Merck Sharp and Dohme
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin degludec, insulin glargine, type 2 diabetes, insulin-naive patients, ultra-long-acting insulin, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, metformin, oral antidiabetic drugs, insulin dose, non-inferiority, treat-to-target, insulin dose adjustment, adverse events
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Treatment Outcome, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.